CAR-T治疗失败后复发难治性大B细胞淋巴瘤的临床试验参与情况
单中心研究分析2018年1月至2023年9月CAR-T治疗后进展的166例复发难治性大B细胞淋巴瘤患者,39%接受筛选、23%入组、22%最终接受试验治疗。高危临床特征与不参与相关,按FDA批准新药的关键试验标准仅14%-36%患者合格。
要点
- CAR-T失败后临床试验参与率低:166例中仅23%入组、22%接受治疗
- ECOG≥2、IV期、高危IPI、CAR-T反应不完全及重度CRS与不参与相关
- 按FDA批准新药的关键试验标准,仅14%-36%复发患者符合条件
核心结论
- CAR-T治疗后进展的复发难治性大B细胞淋巴瘤患者临床试验入组率低,高危特征患者参与更少,需开发容纳高危人群的试验。
研究设计与样本
- 单中心研究,纳入2018年1月至2023年9月CAR-T治疗后进展的复发难治性大B细胞淋巴瘤患者166例,分析筛选、入组和治疗阶段特征。
主要发现
- 166例CAR-T后进展患者中,39%接受筛选,23%入组,22%最终接受试验治疗。
- ECOG评分≥2、IV期疾病、高危国际预后指数、对CAR-T反应不完全及重度细胞因子释放综合征与不参与临床试验相关。
- 采用促使新药获FDA批准的关键试验合格标准,仅14%-36%的CAR-T后复发患者符合这些试验条件。
关键数值与推荐
- 166例中39%筛选、23%入组、22%接受试验治疗。
- 按FDA批准新药的关键试验标准,14%-36%的CAR-T后复发患者合格。
临床怎么用
- 应关注CAR-T失败后高危特征患者,降低试验参与障碍,并设计容纳高危人群的临床试验。
局限性
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More than half of patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) experience progression after chimeric antigen receptor (CAR) T-cell therapy, and subsequent treatment options remain limited with poor outcomes. Despite the need for effective therapies in this setting, post-CAR T clinical trial enrolment is low. We conducted a single-centre study of patients with r/r LBCL who progressed after CAR T-cell therapy between January 2018 and September 2023 to describe the practice patterns and identify factors associated with clinical trial participation. Patient, disease and clinical characteristics were analysed across screening, enrolment and treatment phases. Among 166 patients who progressed after CAR T-cell therapy, 39% were screened, 23% enrolled and 22% ultimately received trial treatment. High-risk clinical features, including eastern cooperative oncology group (ECOG) performance status ≥2, stage IV disease, high-risk International Prognostic Index, incomplete response to CAR T-cell therapy and severe cytokine release syndrome, were associated with non-participation. Using the eligibility criteria of pivotal trials that led to FDA approval of novel agents, only 14%-36% of patients who had relapsed disease after CAR T-cell therapy were eligible for these trials. The study highlights the unmet need to develop trials that accommodate high-risk populations to reduce barriers to trial participation following CAR T-cell therapy failure.
引用
- Kim K, Shah R, Ayers A, et al. Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma. Br J Haematol. 2026. PMID: 41521615. doi:10.1111/bjh.70325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。